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WMM3
MODELING SEQUENTIAL DECISION-MAKING 
IN PHARMACOECONOMICS
Bala MV1, Zarkin GA2
1Centocor, Inc., Malvern, PA, USA; 2Research Triangle 
Institute, Research Triangle Park, NC, USA
WORKSHOP OBJECTIVE: The objective of this work-
shop will be to develop skills in modeling and analyzing
sequential decision-making problems in pharmacoeco-
nomics.
PARTICIPANTS WHO WOULD BENEFIT: Analysts or
decision-makers involved in the conduct or evaluation of
pharmacoeconomic studies.
Most decision problems in pharmacoeconomics involve
sequential decision-making, where the initial decision is
followed by outcomes that affect subsequent decisions.
However, future decisions are rarely explicitly modeled
in most pharmacoeconomic studies. In this workshop we
examine the problems associated with modeling future
decisions as chance events, and describe the advantages
of explicitly incorporating these future decisions in the
decision model. We start by examining the different
classes of decision problems, including decision-making
under certainty, uncertainty, and risk. We describe how
decision trees are an ideal framework for representing se-
quential decision-making problems. We then use an ex-
ample to illustrate how modeling future decisions as
chance nodes can lead to suboptimal decisions. We also
use the example to illustrate how failure to explicitly
model future decisions can lead to erroneous results dur-
ing sensitivity analysis. We describe how models that ex-
plicitly incorporate future decisions can be used to de-
velop optimal treatment pathways. Further, we argue
that we cannot optimize the initial treatment decision
without identifying the optimal treatment pathway. We
explore possible reasons why future decisions are often
represented as chance nodes in pharmacoeconomic mod-
els. Finally, we extend the discussion to Markov models.
We show how future decisions can be modeled through
the use of Markov decision models, which identify the
optimal treatment strategy for each health state. We will
conclude the workshop with an interactive discussion of
the benefits and drawbacks of explicitly modeling future
decisions in pharmacoeconomic models.
WMS3
SOFTWARE FOR COST-EFFECTIVENESS 
STATISTICAL INFERENCE
Obenchain R
Lilly Research Laboratories, Indianapolis, IN, USA
WORKSHOP OBJECTIVE: This workshop will demon-
strate use of free Microsoft Windows software for calcu-
lation and graphical display of Confidence Regions for
Incremental Cost-Effectiveness Ratios (ICERs) using ei-
ther bootstrapping or Fieller’s theorem methodology.
PARTICIPANTS WHO WOULD BENEFIT: Those who
want to learn how to perform cost-effectiveness analyses
and increase their understanding of ICER confidence in-
terval literature will benefit from this workshop.
The workshop will demonstrate application of statistical/
econometric methods that account for uncertainty and
bias in an Incremental Cost-Effectiveness Ratio (ICER)
comparing two treatments. Participants who bring a lap-
top to the workshop will receive a 3.5” IBM disk con-
taining the software being demonstrated; the software
can also be downloaded via the internet from http://
www.math.iupui.edu/indyasa. The workshop will cover
five topics: 1) how to install the software on a personal
computer running Microsoft Windows 95/NT/98; 2)
how to prepare data input files; 3) how to use the soft-
ware’s menu items and dialog boxes; 4) how to interpret
the printed output and graphical displays; 5) how to
choose between alternative ways of reporting results
(graphical display on the cost-effectiveness plane, ICER
slopes, ICER angles, upper and lower confidence limits,
upper and lower tolerance limits, acceptability curves
and quadrant confidence fractions.)
WMS4
STATISTICAL ISSUES IN THE DESIGNING 
AND ANALYZING THE DATA FOR 
PHARMACOECONOMICS AND
OUTCOME STUDIES
Rajagopalan R
Glaxo Wellcome Inc, Research Triangle Park, NC, USA and 
University of North Carolina, School of Pharmacy, Chapel Hill, 
NC, USA
WORKSHOP OBJECTIVE: The purpose of this workshop
is to identify the statistical issues in designing outcome
studies, calculating sample size, planning data analysis, and
interpreting the results. Various alternative methodology
and their benefits and opportunities to improve will be
discussed.
PARTICIPANTS WHO WOULD BENEFIT: Analysts of
cost and effectiveness data and the audience for the liter-
ature of economic evaluations of healthcare measures,
drugs, and devices who want to increase their under-
standing of such literature.
The differences in design between RCTs and pharmaco-
economic studies will be discussed. When we perform
cost-effectiveness comparison, we create cost-effectiveness
ratios and compare them across treatments. If the vari-
ables, costs and effectiveness are normally distributed, it is
very certain that the cost-effectiveness ratio will not be nor-
mally distributed. So we cannot use traditional methods
to compare cost-effectiveness ratios. Therefore calcula-
tion of power, sample size and p-values is only margin-
ally applicable. Next, we also consider modeling for cost-
effectiveness—such as deterministic or stochastic model-
ing, decision analysis, Markov’s processes, longitudinal
